Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Are The Market Size Estimates For The Malignant Pleural Effusion Market?

Significant expansion has been witnessed in the malignant pleural effusion market in the past years. The market, set to escalate from $4.42 billion in 2024 to $4.73 billion in 2025, projects a compound annual growth rate (CAGR) of 6.9%. Factors contributing to the previous period’s growth include the growing use of indwelling pleural catheters, heightened emphasis on palliative care, an increase in the number of clinical trials, improved reimbursement policies, and a swell in metastatic malignancies.

In the forthcoming years, the market size for malignant pleural effusion is predicted to experience robust growth, surging to $6.12 billion in 2029 with a compound annual growth rate (CAGR) of 6.7%. This growth can be ascribed to various factors, such as improvements in healthcare infrastructure, increased government support, a rise in cancer survivorship, a growing demand for home-based care and advancements in liquid biopsy. Some significant trends projected during this period involve the incorporation of artificial intelligence into imaging tools, progress in targeted cancer therapies and pleurodesis techniques, betterment in biomarkers, and a spike in clinical trials for exploring new therapeutic agents.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22047&type=smp

Which Industry Forces Are Driving The Malignant Pleural Effusion Market Forward?

The malignant pleural effusion market’s expansion is anticipated to be fuelled by the increasing incidence of lung cancer. Lung cancer, characterized by the uncontrollable proliferation of abnormal cells in the lungs, can result in tumor formations that hinder typical lung functionality. The spike in lung cancer cases is primarily attributed to smoking and tobacco consumption, as these practices expose individuals to damaging chemicals that harm lung tissues, induce genetic mutations, and foster the rampant growth of cancerous cells, thereby notably heightening the risk of disease contraction. Malignant pleural effusion signifies advanced lung cancer, promoting the dispersion of tumors within the pleural cavity, consequently deteriorating respiratory operation and prognosis. For example, as per the statistics published by the American Cancer Society Facts and Figures, a professional organizations company based in the US, in January 2023, the projected number of new lung and bronchus cancer cases was 236,740 in 2022 and 238,340 in 2023, while the predicted deaths were 130,180 in 2022 and 127,070 in 2023. Therefore, the escalating instances of lung cancer constitute a key driving force propelling the growth of the malignant pleural effusion market.

How Is The Malignant Pleural Effusion Market Organized By Different Segments?

The malignant pleural effusionmarket covered in this report is segmented –

1) By Treatment: Systemic Therapy; Therapeutic Thoracentesis; Thoracic Drainage And Pleurodesis; Indwelling Pleural Catheter

2) By Diagnosis: Pleural Fluid Cytology; Immunohistochemical Tests; Imaging Tests; Pleural Thoracentosis; Pleuroscopy; Pleural Biopsy

3) By End Users: Hospitals; Ambulatory Clinics; Other End Users

Subsegments:

1) By Systemic Therapy: Chemotherapy; Targeted Therapy; Immunotherapy

2) By Therapeutic Thoracentesis: Single-Time Thoracentesis; Repeated Thoracentesis

3) By Thoracic Drainage And Pleurodesis:Chemical Pleurodesis; Mechanical Pleurodesis; Biological Pleurodesis

4) By Indwelling Pleural Catheter:Tunneled Pleural Catheter; Non-Tunneled Pleural Catheter

What Future-Focused Trends Are Anticipated In The Malignant Pleural Effusion Market?

In the malignant pleural effusion market, major companies are developing novel enzyme-targeting therapies designed to improve treatment outcomes by focusing on enzymes involved in fluid buildup. Enzyme-targeting therapy involves drugs that specifically inhibit or alter enzyme activity linked to disease progression, commonly applied in cancer, metabolic, and infectious diseases. For example, in September 2022, US-based RS Oncology, LLC began the MITOPE clinical trial—a first-in-human Phase 1/2 study conducted in the UK. The trial evaluates RSO-021, a new PRX3 inhibitor intended to treat malignant pleural effusion and mesothelioma by targeting oxidative stress to destroy cancer cells while protecting healthy tissue.

Who Are The Primary Market Leaders In The Malignant Pleural Effusion Market?

Major companies operating in the malignant pleural effusion market are Pfizer Inc., Merck & Co. Inc., Novartis International AG, Bristol-Myers Squibb Company, Gilead Sciences Inc., Amgen Inc., Medline Industries LP, Becton Dickinson and Company, Cook Medical LLC, Merit Medical Systems Inc., Argon Medical Devices Inc., B Braun SE, Simcere Pharmaceutical Group Limited, pfm medical AG, Redax SpA, Wuhan YZY Biopharma Co. Ltd., Rocket Medical plc, Genelux Corporation, Gongwin Biopharm Holdings Co. Ltd., Ewimed GmbH

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/malignant-pleural-effusion-global-market-report

How Do Regional Dynamics Influence The Malignant Pleural Effusion Market Performance?

North America was the largest region in the malignant pleural effusion market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant pleural effusion market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=22047&type=smp

Browse Through More Reports Similar to the Global Malignant Pleural Effusion Market 2025, By The Business Research Company

Adult Malignant Glioma Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

Malignant Melanoma Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/malignant-melanoma-treatment-global-market-report

Breast Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model